Leucemia Mieloide Cronica: la terapia con imatinib
|
|
- Leon Shelton
- 6 years ago
- Views:
Transcription
1 42 CONGRESSO NAZIONALE SIE Società Italiana di Ematologia Milano, ottobre 2009 Leucemia Mieloide Cronica: la terapia con imatinib Francesca Palandri Dipartimento di Ematologia e Oncologia L. e A. Seràgnoli Bologna University Hospital
2 Imatinib standard dose: IRIS 7-year update 2
3 IRIS Protocol: Study Design R A N D O M I Z E Imatini b n = 553 IFN-a + Ara-C n = 553 Crossover Crossover for: Lack of response Loss of response Intolerance of treatment Reluctance to continue IFN O BRIEN et al, NEJM,
4 IRIS: 7-year update All randomized to imatinib (n= 553; 100%) Still receiving study imatinib (n = 332; 60%) Discontinued study imatinib* (n = 221; 40%) In CCR (n = 317; 97%) No CCR (n = 15; 3%) Safety (5%) Efficacy (15%) Other (22%) Cumulative CCgR rate: 456/553 (82%) Alive (40%) Dead (60%) 164 alive patients (30%) Alive (63%) Dead (37%) formally off protocol Alive (84%) Dead (16%) *Patients may have continued imatinib off study. Hochhaus A et al,leukemia
5 IRIS- Molecular Response % of available samples BCR-ABL% (International Scale) 0.1% (MMolR) 0.01% Months from imatinib start O BRIEN et al, ASH 2008, Blood 2008; 112(11): 76, Abstract 186 5
6 Overall Survival (ITT Principle) % % % alive Survival: deaths associated with CML Overall Survival Months Since Randomization O BRIEN et al, ASH 2008, Blood 2008; 112(11): 76, Abstract 186 6
7 Imatinib standard dose: Indipendent analyses 7
8 De Lavallade et al, JCO 2008; 26: Patients number High Sokal Intermediate Sokal Low Sokal Median follow-up, mos (29%) 86 (42%) 59 (29%) 38 (12-85) OS 83% PFS 82% EFS* 63% no of patients (%) CHR CCgR MMolR 201 (98%) 159 (78%) 80 (39%) Event: death, progression to AP/BC, loss of CHR/MCgR, IM discontinuation for AE/ failure to achieve a PCgR 8
9 : analysis of 553 Early Chronic Phase patients accrued between 2004 and 2007 in 3 multicentric studies Complete cytogenetic response rate 100% 80% 60% 40% 20% 0% 68% 79% 79% 6 mos 12 mos 18 mos OS: 93% PFS: 92% FFS: 82% EFS: 74% Failures: no CHR at 6 mos, no CgR at 6 mos, no PCgR at 12 mos, no CCgR at 18 mos, loss CHR or CCgR, progression to accelerated/blastic phase and death. Events: failures, off-treatment for toxicity, refusal and lost to follow-up. 9
10 Beyond imatinib standard dose: room for improvements with higher doses? 10
11 Imatinib dose optimization The issue is complex and probably it cannot be applied, or pursued, in all patients irrespective of 1) Response 2) Tolerance 3) Blood level testing data Rational for higher doses of IM 1) Responses to 800mg after failure to 400mg 2) Chronic phase: Response correlates with actual dose intensity 3) Accelerated phase 600 mg (vs 400 mg): improved response rate, survival and EFS 4) Some mechanisms of resistance may be overcome by higher dose 11
12 Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study Cortes et al., JCO 2009, in press Random 2:1 N=476 N=319 pts N=157 pts Imatinib 800 mg Imatinib 400 mg MMR at 12 months PFS, OS Total 5 years Accrual: June 2005 December 2006 Follow-up: 12 months 12
13 TOPS study: IM 400 mg vs 800 mg 100% CCgR 80% 60% p p NS 70% 40% 57% 66% 45% 20% 0% 400 mg 800 mg 400 mg 800 mg 6 mos 12 mos 100% MMolR By 12 months, CCgR and MMR rates were comparable between 400 and 800 mg/day arms 80% 60% 40% 20% 0% p NS p % 40% 34% 17% 400 mg 800 mg 400 mg 800 mg 6 mos 12 mos 13
14 R A N D O M I Z E Imatinib 400mg Imatinib 800mg Primary Endpoint: CCgR at 1 year FAILURES Lack of CHR at 6 months Less than minor CyR at 6 months Less than Partial CyR at 12 months Loss of CHR Loss of CCyR 14
15 ELN CML022 study 100% CCgR 80% 60% 40% 52% p NS 50% 64% p NS 58% HIGH DOSE ARM CCgR according to average daily dose 20% 100% 0% 400 mg 800 mg 400 mg 800 mg 6 mos 12 mos 80% 60% 91% 73% 40% 100% 80% 60% p NS MMolR p NS 20% 0% 20% <400 40% 20% 42% 32% 49% 41% CCyR rates appeared to be related to the actual dose 0% 400 mg 800 mg 400 mg 800 mg 6 mos 12 mos 15
16 Beyond imatinib alone: room for improvements with combination therapies? 16
17 GIMEMA CML 011- IM+PegIFN-α in 76 ECP-CML % Cytogenetic response rate (5 yrs) overall survival % 80% 60% 87% months 40% 20% 0% Partial 10% Complete progression-free survival months 95% 17
18 GIMEMA CML 011 Compliance to PegIFN-α 45% 35% 41% 1st cohort 2nd cohort 3rd cohort 25% 18% 15% 5% 13% 3% 0% 12 mos 18 mos 24 mos 36 mos 18
19 French SPIRIT trial 636 ECP patients Imatinib 400 mg Randomization 1:1:1:1 Study initiation: Sept 2003 Imatinib 600 mg Imatinib 400 mg + Ara-C Imatinib 400 mg + PegIFN Courtesy of dr. F. Guilhot 19
20 SPIRIT: Major Molecular Response at 18 months (ITT) Courtesy of dr. F. Guilhot 1 62% IM + IFN IM 600 P= IM + AraC 41% 41 IM % of the patients discontinued IFN during the first year. Guilhot F, et al. Bood (ASH Annual Meeting Abstracts) 112:183,
21 German CML Study IV Imatinib n=336 Imatinib + IFNa n=362 Failure No significant differences between treatment arms for CCgR, MMolR and PFS R Imatinib + AraC n=158 Imatinib after IFNa n=131 Imatinib 800 mg n=350 allosct n=84 Median follow-up: 45 months Hehlmann R. Haematologica 2009; 94:193 Courtesy of dr. R. Helhhman 21
22 Beyond imatinib: room for therapy discontinuation? 22
23 The STop IMatinib ( STIM ) study Molecular relapse in 36 pts 15/34 (44%) LCP 21/36 (58%) ECP Median follow-up: 4 mos (1-20) Courtesy dr. P Rousselot 23
24 SUMMARY 1. IM 400 mg daily in early chronic phase CML: CHR 95% CCgR 75-90% MMolR 50-70% 7-yrs PFS 85-90% 7-yrs OS 90-95% 2. IM 800 mg: cytogenetic and molecular responses more rapid, but no differences at 1 year. Limited compliance. 3. IM in combination/rotation with other agents is investigational. The feasibility of the combination with IFN-alpha seems to be limited. 24
25 OPEN ISSUES 1. Imatinib is not always a magic bullet D/C IMATINIB FOR FAILURE 15-20% D/C IMATINIB FOR TOXICITY 8-10% MMolR RATE 40-90% 2. Imatinib and Quality of Life 3. Imatinib and safe procreation 4. Imatinib and CURE 25
26 Thank you! Scientific Commitee Michele Baccarani (Bologna) Giuliana Alimena (Roma) Renato Fanin (Udine) Francesco Frassoni (Genova) Giovanni Martinelli (Bologna) Gianantonio Rosti (Bologna) Domenico Russo (Brescia) Giuseppe Saglio (Torino) Giorgina Specchia (Bari) Department of Hematology L. and A. Seràgnoli Bologna University Hospital 26
27 BACK-UP 27
28 IRIS: 7-year update Annual Event Rates % With Event All patients Event Loss of CHR, Loss of MCR, AP/BC, Death during treatment AP/BC Year EFS at 7 years:81% PFS at 7 years:93% Number Progressing After CCR * CCgR patients 1 3 Event 1 AP/BC Loss of CHR Loss of MCR AP/BC Death Time to CCR 12 months (n = 373) >12-24 months (n = 50) >24 months (n = 33) 1st 2nd 3rd 4th 5th Year After Achievement of CCR 28
29 : ITT ANALYSIS 559 Early Chronic Phase patients accrued between Jan 2004 and Apr 2007 in 3 multicentric studies: CML/021, phase II 82 pts imatinib 800 mg in intermediate Sokal risk CML/022, phase III, randomized 112 pts imatinib 400 vs 800 mg in high Sokal risk CML/023, observational 365 pts imatinib 400 mg, all risks 29
30 ELN CML022 study: IM 400 mg vs 800 mg in high risk pts Treatment discontinuation in the first year Withdrawals Adverse events Failures Total 400 (n. 108) 5% 5% 17% 27% 800 (n. 108) 8% 8% 15% 31% Average daily dose 800 mg 400mg 800 mg 28% NA 53% % NA % 57% % 31% <350 6% 12% 30
31 Evaluating Response in CML CHR Hematologic response Number of leukemic cells MCR CCR (CG) CCR (FISH) 3 log reduction 4 log reduction Limits of detection Cytogenetic response Molecular response (Q-PCR) 1 31
32 Late chronic phase Accelerated/blast phase 32
33 GIMEMA CML 002: Imatinib in Late Chronic Phase CML OS / PFS OS PFS 90% Months from IM start Patients in CCgR early late Months from IM start Palandri et al,, JCO
34 GIMEMA CML 003: Imatinib 600 mg in Accelerated/blast Phase Blast crisis Accelerated phase Number of patients Male/female Median age at IM start 92 59/33 55 (18-88) /41 58 (26-82) ACA at IM start PS at IM start =2 Chemotherapy prior to IM 20 (22%) 36 (39%) 27 (29%) 21 (22%) 18 (16%) 29 (26%) 34
35 GIMEMA Overall survival overall survival HR no HR months from IM start overall survival months from IM start overall survival MCgR no MCgR months from IM start overall survival months from IM start BC patients AP patients 35
36 DOSE ISSUE 36
37 Imatinib high dose: rationale 1. Dose-response in preclinical models 2. Phase I: No MTD, dose-response correlation 3. Responses to 800mg after failure to 400mg 4. Accelerated phase 600 mg (vs 400 mg): improved response rate, survival and EFS 5. Chronic phase: Response correlates with actual dose intensity, plasma levels 6. Improved long-term outcome with early responses 7. Some mechanisms of resistance may be overcome by higher dose 37
38 Therapeutic Intensification in DE- novo Leukaemia (TIDEL STUDY) Australasian Leukaemia and Lymphoma Group Dose escalation to 800 mg IM 600 mg No CHR No PCgR No CCgR No MMolR 3 months 6 months 9 months 12 months Accrual: October August 2003 No. of patients:
39 TIDEL STUDY response rate CCgR MMolR 100% 80% 60% 40% p % 88% p % 90% 47% p N.S. 55% 73% 20% 40% 0% IRIS TIDEL IRIS TIDEL IRIS TIDEL IRIS TIDEL 12 mos 24 mos 12 mos 24 mos Patients able to dose escalate and those remaining on 600 mg achieved superior responses to patients receiving 600 mg. Superior responses achieved in patients able to tolerate imatinib at 600 mg suggests that early dose intensity may be critical to optimise response in CP-CML 39
40 Study Sokal Intermediate Risk IM 800 mg (72 pts) 3 months 6 months 12 months No Observed CHR 81% 98% 98% PHR 19% 2% // ABP // 1% 2% Minimal/absent 4% 3 Minor 1% 0 PCgR 8% 3% CCgR 87% 90% 40
41 Comparison IRIS Houston Houston GIMEMA TIDEL 400 mg 400 mg 800 mg 800 mg 600 mg (021) CCyR Overall 82% 80% 95% 91% NA 6 months 52% 55% 82% 87% 80% 12 months 68% 75% 95% 90% NA MMR 6 months 21% 5% 39% 46% 31% 12 months 39% 25% 60% 48% 43% m9 24 months 55% 60% 72% NA NA PCR undetectable 4% 7% 28% NA NA 41
42 COMBINATION THERAPIES 42
43 GIMEMA CML 0408 NILO 400 mg BID IM 400 mg OAD NILO 400 mg BID IM 400 mg OAD > 24 months CORE > 36 months EXTENSION 3-days wash out 43
44 GIMEMA CML 011- IM + PegIFN-α in de-novo CP-CML Male, no. (%) Female, no. (%) Median age at diagnosis, yrs, (range) Median time on pegifnα, mos (range) Median follow-up of living patients, mos, (range) All patients (76) 44 (58%) 32 (42%) 47 (18-68) 10 (0.5-49) 60 (40-68) 1st cohort (27 patients) 50 µg/week 2nd cohort (18 patients) 100 µg/week 3rd cohort (31 patients) 150 µg/week 44
45 VACCINOTERAPIA vaccino antitumorale IDEALE induce una risposta immune sistemica ATTIVA distrugge specificatamente cellule tumorali disseminate da origine ad una memoria immunologica persistente OSTACOLI Identificare l ANTIGENE P 210 TUMORALE SPECIFICO TARGET TUMORE-SPECIFICO più appropriato P 210 IMMUNOGENICO Rompere la TOLLERANZA GRAZIE A SEQUENZA IMMUNOLOGICA AMINOACIDICA al tumore UNICA 45
46 CMLVAX100: STUDIO DI FASE II CRITERI DI INCLUSIONE diagnosi di LMC b3a2 almeno 1 di HLA A3, A11, B8, DR11, DR1 o DR4 Risposta citogenetica maggiore o completa STABILE da almeno 6 mesi durante trattamento convenzionale (IFN-α o IMATINIB) DOSE VACCINO 5 PEPTIDI: 100µg/peptide (500µg/iniezione) QS-21: 100µg GM-CSF: 50µg/m 2 PIANO DI TRATTAMENTO 6 vaccinazioni ogni 2 settimane (IMMUNIZAZIONE) + richiami ogni 4-6 mesi dal termine (MANTENIMENTO) 46
47 CMLVAX100 peptide vaccine: summary clinical results 23 patients with various degrees of cytogenetically and/or molecularly defined MRD persisting after a median time of 2 years of imatinib treatment entered the vaccination protocol 15/23 (65%) pts measurably reduced their levels of residual disease after immunization (6 vaccinations) 6/23 (26%) pts achieved a CMR after immunization Clinical responses were durable and tended to improve further after boosts of vaccine 47
48 IM SAFETY 48
49 IRIS SAEs in Years 6 and 7 No unique, previously unreported AEs attributed to imatinib observed over the past 24 months In years 6 and 7, 13 SAEs with suspected relationship to imatinib were reported: Congestive Heart Failure (n=3): all of the patients had pre-existing cardiac disease prior to study entry Second malignancy (n=3)* Myositis (n=1); elevated CK (n=1); multiple sclerosis (n=1) Pancreatitis (n=1); vomiting (n=1) Renal failure (n=1) Dermatitis (n=1) *With >400,000 patient years of estimated imatinib exposure, the analysis of clinical safety data from clinical trials and spontaneous reports did not provide evidence for an increased incidence of malignancies for patients treated with imatinib compared to that of the general population 49
50 The issue of cardiotoxicity Here we report ten individuals who developed severe congestive heart failure while on imatinib and we show that imatinibtreated mice develop left ventricular contractile dysfunction. KERKELA et al, NATURE MEDICINE 2006; 12:
51 IN REPLY TO CARDIOTOXICITY OF THE CANCER THERAPEUTIC AGENT IMATINIB MESYLATE Nature Medicine 2007; 13: NO. OF YEARS PTS NO. % OF % OF YEARS PTS EXPOSURE CHF PTS PTS EXPOSURE HATFIELD et al NOVARTIS GAMBACORTI et al MILANO <0.97 <0.24 ATALLAH et al M.D. ANDERSON * ROSTI et al ** <0.12 <0.04 TOTAL *22 RECORDED, 7 CONFIRMED ** 3 CASES OF MYOCARDIAL INFA RCTUS 51
52 Imatinib and pregnancy 52
53 Current Recommendations Data still not conclusive BUT estimated risk of foetal abnormalities 7-10% It is currently advised to avoid imatinib in pregnancy unless absolutely essential. Women of child-bearing age receiving imatinib should take adequate contraceptive measures. In case of accidental pregnancy, a risk-benefit evaluation on an individual basis 53
54 Exposure To Imatinib During Pregnancy Imatinib is teratogenic, embryotoxic (not genotoxic) and causes increased rates of post implantation loss Clinical trials excluded pregnant women Most pregnancies are unplanned Insufficient data available yet Specific pharmacovigilance requested 54
55 Outcome known for 128/180 (63%) Pregnancy outcome Total number (%) with known outcome n=125 (%) of total n=180 Normal Live Infant Elective Termination* Foetal Abnormality Spontaneous Abortion * Includes 3 terminated following identification of fetal abnormalities 55
56 Imatinib and Plasma level testing 56
57 DISTRIBUTION OF IMATINIB TROUGH LEVELS (N = 351) (IRIS STUDY) Number of Patients Quartile 1 <647 ng/ml N=87 Quartiles 2 and ng/ml N=178 Quartile 4 >1170 ng/ml N= Imatinib Trough Level in ng/ml (Day 29) Larson R. et al, Blood. 2008;111:
58 Imatinib Trough Levels IS AN INDEPENDENT PROGNOSTIC FACTOR FOR CCgR p=0.004 by Wilcoxon test 1009± ±409 N=297 N=54 Larson R. et al, Blood. 2008; 110,
HOW I TREAT CML. 4. KONGRES HEMATOLOGOV IN TRANSFUZIOLOGOV SLOVENIJE Z MEDNARODNO UDELEŽBO Terme Olimia, Podčetrtek,
HOW I TREAT CML 4. KONGRES HEMATOLOGOV IN TRANSFUZIOLOGOV SLOVENIJE Z MEDNARODNO UDELEŽBO Terme Olimia, Podčetrtek, 12. - 14. april, 2012 Gianantonio Rosti Dpt of Hematology and Oncological Sciences S.
More informationELN Recommendations on treatment choice and response. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
ELN Recommendations on treatment choice and response Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy ELN 2013 Response to Front-line Treatment Baseline 3 months 6 months OPTIMAL
More informationRole of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML. GIUSEPPE SAGLIO, MD University of Torino, Italy
Role of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML GIUSEPPE SAGLIO, MD University of Torino, Italy Outcome in 282 Patients Treated with Imatinib First Line in Hammersmith Hospital
More informationImatinib dose intensification, combination therapies. Andreas Hochhaus Universitätsklinikum Jena, Germany
Imatinib dose intensification, combination therapies Andreas Hochhaus Universitätsklinikum Jena, Germany Apperley JF. Lancet Oncol. 2007 High OCT-1 activity is associated with faster MMR in imatinib treated
More informationVenice Meeting Highlights: Key lessons. Conclusions Michele Baccarani Rüdiger Hehlmann
Venice Meeting Highlights: Key lessons Conclusions Michele Baccarani Rüdiger Hehlmann CML therapy in the imatinib era CML prognosis has improved dramatically Cellular and molecular biology studies help
More informationNew drugs in first-line therapy
New drugs in first-line therapy Gianantonio Rosti Dept of Hematology and Oncology Seràgnoli, Bologna University (Italy) GIMEMA (Gruppo Italiano Malattie Ematologiche dell Adulto) CML WORKING PARTY IRIS
More informationNEW DRUGS IN HEMATOLOGY
NEW DRUGS IN HEMATOLOGY BOLOGNA, 15-17 April 2013 TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA MICHELE BACCARANI michele.baccarani@unibo.it Historic Development of CML Therapy Palliative Therapy
More informationIRIS 8-Year Update. Management of TKI Resistance Will KD mutations matter? Sustained CCyR on study. 37% Unacceptable Outcome 17% 53% 15%
Management of TKI Resistance Will KD mutations matter? IRIS 8-Year Update 17% 53% 5% 15% 37% Unacceptable Outcome No CCyR Lost CCyR CCyR Other 3% 7% Safety Lost-regained CCyR Sustained CCyR on study Deininger
More informationCML: Living with a Chronic Disease
CML: Living with a Chronic Disease Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia M. D. Anderson Cancer Center Houston, Texas Survival in Early Chronic Phase CML TKI Interferon Chemotherapy
More informationEUROPEAN LEUKEMIANET RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
EUROPEAN LEUKEMIANET RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA SAN DIEGO, 11 DECEMBER 2011 AMSTERDAM, 14 JUNE 2012 BALTIMORE, 20 SEPTEMBER 2012 ATLANTA, 6 DECEMBER 2012 ELN, CML Panel Jane Apperley
More informationCML EHA: what s new? Novità dall EHA >> [ Leucemia mieloide cronica ] Relatore: G. MARTINELLI. Borgo S. Luigi Monteriggioni (Siena) ottobre 2008
Novità dall EHA >> [ Leucemia mieloide cronica ] CML EHA: what s new? Relatore: G. MARTINELLI 27-28 ottobre 2008 Borgo S. Luigi Monteriggioni (Siena) Leucemia mieloide cronica - Copyright FSE 1 CML EHA:
More informationChronic Myeloid Leukaemia
Chronic Myeloid Leukaemia Molecular Response: What is really important? Jeff Szer The Royal Melbourne Hospital PROBABILITY, % PROBABILITY OF SURVIVAL AFTER MYELOABLATIVE TRANSPLANTS FOR CML IN CHRONIC
More informationDati sulla sospensione della terapia
Leucemia Mieloide Cronica Dati sulla sospensione della terapia Gianantonio Rosti, Bologna BCR-ABL Loading in CML Patients 100% 10% 1% MMR MR 4 MR 4.5 STIM study design N=100 Start Imatinib CMR Sustained
More information2 nd Generation TKI Frontline Therapy in CML
2 nd Generation TKI Frontline Therapy in CML Elias Jabbour, M.D. April 212 New York Frontline Therapy of CML in 212 - imatinib 4 mg daily - nilotinib 3 mg BID - dasatinib 1 mg daily Second / third line
More informationGuidelines and real World: Management of CML in chronic and advanced phases. Carolina Pavlovsky. FUNDALEU May 2017 Frankfurt
Guidelines and real World: Management of CML in chronic and advanced phases Carolina Pavlovsky. FUNDALEU 26-28 May 217 Frankfurt Some Issues in CML 217 First Line treatment: Imatinib vs 2nd generation
More informationThe concept of TFR (Treatment Free Remission) in CML
The concept of TFR (Treatment Free Remission) in CML Giuseppe Saglio University of Turin, Italy What can we expect today on long-term therapy with TKIs in CML? German CML study IV Relative and overall
More informationCML: Yesterday, Today and Tomorrow. Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center
CML: Yesterday, Today and Tomorrow Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Five Years of Signal Transduction Inhibition The Beginning
More information2nd generation TKIs to first line therapy
New Horizons 2011 Newly diagnosed CML moving 2nd generation TKIs to first line therapy Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA
More informationStopping Treatment in CML and dose reduction in clinical practice: Can we do it safely? YES WE CAN!
Stopping Treatment in CML and dose reduction in clinical practice: Can we do it safely? YES WE CAN! Dragana Milojković The Hammersmith Hospital, London, UK Leukemic burden Current Aim of TKI therapy Molecular
More informationWhen to change therapy? Andreas Hochhaus Universitätsklinikum Jena, Germany
When to change therapy? Andreas Hochhaus Universitätsklinikum Jena, Germany Chromosome 22 Chromosome 9 e1 1b m-bcr M-bcr e1 e2 b1 b5 5 3 BCR ABL 5 3 1a a2 a3 μ -bcr e19 a11 e1a2 b2a2 b3a2 e19a2 p190 bcr-abl
More informationOxford Style Debate on STOPPING Treatment.
Oxford Style Debate on STOPPING Treatment. This house believes that there are good reasons NOT to stop CML treatment. It should be done within clinical trials, OR only in expert centers where frequent,
More informationHow I treat high risck CML
Torino, September 14, 2018 How I treat high risck CML Patrizia Pregno Hematology Dept. Citta della Salute e della Scienza Torino Disclosures Advisory Board: Novartis, Pfizer, Incyte Speaker Honoraria:
More informationManagement of CML in blast crisis. Lymphoma Tumor Board November 27, 2015
Management of CML in blast crisis Lymphoma Tumor Board November 27, 2015 Chronic Phase CML - 2. Peter Maslak, ASH Image Bank 2011; 2011-2455 Copyright 2011 American Society of Hematology. Copyright restrictions
More informationJuan Luis Steegmann Hospital de la Princesa. Madrid. JL Steegmann
Juan Luis Steegmann Hospital de la Princesa. Madrid. Juan Luis Steegmann Hospital de la Princesa. Madrid No rush,at least in Chronic Phase Blast Phase*: SCT asap, after restablishing CP with TKI Accelerated
More informationContemporary and Future Approaches in CML. Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D.
Contemporary and Future Approaches in CML Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D. 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal Indolent Prognosis
More informationRESEARCH ARTICLE. Introduction. Methods Wiley Periodicals, Inc.
BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase AJH Dennis (Dong Hwan) Kim, 1 * Nada Hamad,
More informationSESSION III: Chronic myeloid leukemia PONATINIB. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
SESSION III: Chronic myeloid leukemia PONATINIB Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy Ponatinib A Pan-BCR-ABL Inhibitor Rationally designed inhibitor of BCR- ABL
More informationContemporary and Future Approaches in Management of CML. Disclosures
Winship Cancer Institute of Emory University Contemporary and Future Approaches in Management of CML Hagop Kantarjian, MD Chairman and Professor, Department of Leukemia University of Texas M. D. Anderson
More informationI nuovi guariti? La malattia minima residua nella leucemia mieloide cronica. Fabrizio Pane
I nuovi guariti? La malattia minima residua nella leucemia mieloide cronica Fabrizio Pane What could be the concept of Cure in CML? Sustained DMR with or without TKI therapy And 100% CML-related survival
More informationCML David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML Current treatment options for CML
1 CML 2012 LLS Jan 26, 2012 David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML 2012 Current treatment options for CML patients Emerging therapies for CML treatment
More informationHistory of CML Treatment
History of CML Treatment Eduardo Olavarria No conflict of interest Lisbon, 20th March 2018 #EBMT18 www.ebmt.or What is CML? The mystery of chronic myeloid leukaemia Chronic myeloid leukaemia Often diagnosed
More informationCML CML CML. tyrosine kinase inhibitor CML. 22 t(9;22)(q34;q11) chronic myeloid leukemia CML ABL. BCR-ABL c- imatinib mesylate CML CML BCR-ABL
1 Key Wordschronic myeloid leukemiaimatinib mesylate tyrosine kinase inhibitor chronic myeloid leukemia CML imatinib mesylate CML CML CML CML Ph 10 1 30 50 3 5 CML α IFNα Ph Ph cytogenetic response CRmajor
More informationLa terapia della LMC: è possibile guarire senza trapianto? Fabrizio Pane
La terapia della LMC: è possibile guarire senza trapianto? Fabrizio Pane What could be the concept of Cure in CML? Sustained DMR with or without TKI therapy And 100% CML-related survival And QoL comparable
More informationOutlook CML 2016: What is being done on the way to cure
New Horizons 2011 Outlook CML 2016: What is being done on the way to cure Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA CML Working Party
More informationWhat is New in CML in Hagop Kantarjian, M.D. February 2011
What is New in CML in 2011 Hagop Kantarjian, M.D. February 2011 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal Indolent Prognosis Poor Excellent 10-yr survival 10% 84-90%
More information10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD
10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD Dalia Khan 1, Noemi Roy 1, Vasha Bari 1, Grant Vallance 1, Helene Dreau 1, Timothy Littlewood 1, Andrew Peniket 1, Paresh Vyas
More informationBMS Satellite Symposium
ICKSH 2018 BMS Satellite Symposium Emerging Trends in CML Management CHAIRMAN The Head of Catholic Hematology Hospital The Director of the Catholic Leukemia Research Institute at the Catholic University
More informationA 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable.
1 Case 1 A 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable. CBC and bone marrow aspiration and biopsy were done. Chromosome study showed she had t(9;22)
More informationCML: definition. CML epidemiology. CML diagnosis. CML: peripheralbloodsmear. Cytogenetic abnormality of CML
MolecularDiagnostic.be Third Scientific Meeting Molecular Diagnostics.be t(9;22) CML: definition Management of CML patients treated with TKI: the place of molecular monitoring Antwerp, December 13 th 11
More informationCML Update 2016 Arthur 2016
CML Update 2016 Chronic Myeloid Leukemia Splenomegaly CML (3 phase disease) Increased white cells Malignant proliferation of myeloid white cells Initially mature cells a) chronic phase of disease Evolution
More information1794 Updating Long-Term Outcome of Intermittent Imatinib. (INTERIM) Treatment in Elderly Patients with Ph+-CML
738 What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia (CML) after Imatinib Loses Patent Exclusivity? https://ash.confex.com/ash/2014/webprogram/paper71699.html
More informationWhat Can We Expect from Imatinib? CML Case Presentation. Presenter Disclosure Information. CML Case Presentation (cont)? Session 2: 8:15 AM - 9:00 AM
Welcome to Master Class for Oncologists Session 2: 8:15 AM - 9: AM Miami, FL December 18, 29 Chronic Myelocytic Leukemia: Imatinib and Beyond Speaker: Daniel J. DeAngelo, MD, PhD Dana-Farber Cancer Institute
More informationTreatment free remission in CML: from the concept to practice. François-Xavier Mahon. Cancer Center Bordeaux Université Bordeaux, France
Treatment free remission in CML: from the concept to practice François-Xavier Mahon Cancer Center Bordeaux Université Bordeaux, France CML is a model 1960 1970 1980 1990 2000 2010 Philadelphia chromosome
More informationDecision Making in CML 2010
Decision Making in CML 2010 Imatinib is the standard treatment for chronic myeloid leukaemia (CML), but approximately 25% of patients are resistant or non-responsive to imatinib. 1 While physicians have
More informationDose reduction. What do we know and how we do it in clinical practice. Andreas Hochhaus
Dose reduction. What do we know and how we do it in clinical practice. Andreas Hochhaus Hadera I Oct 2018 Front-line Randomized Trials in CML-CP Trial Drugs References IRIS IM 400 vs IFN/AraC TOPS IM
More informationLow doses of tyrosine kinase inhibitors in CML
CML Horizons Conference Warsaw 4-6 May 2018 Low doses of tyrosine kinase inhibitors in CML Delphine Rea, MD, PhD Pôle Hématologie Oncologie Radiothérapie INSERM UMR-1160 Centre Hospitalo-Universitaire
More informationThe current standard of care in CML. Gianantonio Rosti, MD University of Bologna Bologna, Italy
The current standard of care in CML Gianantonio Rosti, MD University of Bologna Bologna, Italy CML: Overall Survival 1898-1977 just to remember Clinical Landmarks in CML 1845 1865 1879 1903 1953 1965 1968
More informationMolecular pathogenesis of CML: Recent insights
Napoli 24 gennaio 2012 Molecular pathogenesis of CML: Recent insights Giuseppe Saglio University of Turin CML Biology CML Clinical practice MILESTONES IN MOLECULAR BIOLOGY OF CML 1960 - Nowell P.C. & Hungerford
More informationThe BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine
At the center of advances in hematology and molecular medicine Philadelphia chromosome-positive chronic myeloid leukemia Robert E. Richard MD PhD rrichard@uw.edu robert.richard@va.gov Philadelphia chromosome
More informationSecond-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase
Critical Reviews in Oncology/Hematology 82 (2012) 159 170 Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase Gianantonio Rosti, Fausto Castagnetti,
More informationCML: Role of combination treatments, Interferon and immunotherapy in CML
CML: 2017 Role of combination treatments, Interferon and immunotherapy in CML Andreas Burchert Philipps Universität Marburg Universitätsklinikum Gießen und Marburg GmbH Key Developments that will Change
More informationWhat is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR
What is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR after 18 months of imatinib? Second generation TKIs as a bridge to allogeneic SCT
More informationImatinib & Ponatinib. Two ends of the spectrum in 2016s reality
Imatinib & Ponatinib Two ends of the spectrum in 2016s reality CML 2016 Benefits & risks Steve O Brien CML Horizons, May 2016 Disclosures Research funding, participation in company trial, speaker, consultant,
More informationLEUKEMIA ANCO s ASH Highlights TOPICS
LEUKEMIA ANCO s ASH Highlights Bruno Medeiros, MD 02/10/2009 TOPICS CML Abstract 181 and 182 Abstract 186 and 335 CLL Abstract 325 and 45 APL Abstract 138 ALL Abstract 427 and 428 1 CML Rosti et al. High
More informationState of the Art Therapy and Monitoring of CML Hagop Kantarjian, M.D. Grand Rounds Hackensack, New Jersey. September 22, 2010
State of the Art Therapy and Monitoring of CML - 2010 Hagop Kantarjian, M.D. Grand Rounds Hackensack, ew Jersey September 22, 2010 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course
More informationWhat is New in CML Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia MD Anderson Cancer Center Houston, Texas
What is New in CML 2018 Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia MD Anderson Cancer Center Houston, Texas Final Results CML-IV Molecular Response with Imatinib 1538 pts newly
More informationState of the Art Therapy and Monitoring of CML Hagop Kantarjian, M.D. Grand Rounds UT Southwestern. October 28, 2010
State of the Art Therapy and Monitoring of CML - 2010 Hagop Kantarjian, M.D. Grand Rounds UT Southwestern October 28, 2010 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal
More informationResponse to treatment with imatinib mesylate in previously treated chronic-phase chronic myeloid leukemia patients in a hospital in Brazil
Response to treatment with imatinib mesylate in previously treated chronic-phase chronic myeloid leukemia patients in a hospital in Brazil C.A.P. Silveira 1, M.B. Daldegan 1 and I. Ferrari 2 1 Núcleo de
More informationMRD in CML (BCR-ABL1)
MRD in CML (BCR-ABL1) Moleculaire Biologie en Cytometrie cursus Barbara Denys LAbo Hematologie UZ Gent 6 mei 2011 2008 Universitair Ziekenhuis Gent 1 Myeloproliferative Neoplasms o WHO classification 2008:
More informationFerrata Storti Foundation
Published Ahead of Print on March 19, 2010, as doi:10.3324/haematol.2009.021246. Copyright 2010 Ferrata Storti Foundation. Early Release Paper The response to imatinib and interferon-α is more rapid than
More informationStarting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019
Starting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019 Disclosures Richard A. Larson, MD Research funding to the University
More informationNew drugs and trials. Andreas Hochhaus
New drugs and trials. Andreas Hochhaus Hadera I Oct 2018 Introduction ABL001 is a potent, specific inhibitor of BCR-ABL1 with a distinct allosteric mechanism of action BCR-ABL1 Protein Binds a distinct
More informationThe perspective of generic drugs in chronic myeloid leukemia. Ivana Urosevic
Clinic of hemathology Clinical centre Vojvodina School of Medicine University of Novi Sad, Serbia The perspective of generic drugs in chronic myeloid leukemia Ivana Urosevic Generic Imatinib The potential
More informationCML and Future Perspective. Hani Al-Hashmi, MD
CML and Future Perspective Hani Al-Hashmi, MD Objectives Learning from CML history Outcome of interest to clinician Patient and community interest!! Learning from CML history Survival Probability (All
More informationC Longer follow up on IRIS data
hronic Myeloid Leukemia Drs. Rena Buckstein, Mervat Mahrous & Eugenia Piliotis with input from Dr. J. Lipton (PMH) Updated August 2008* Updates: C Longer follow up on IRIS data Guidelines for monitoring
More informationChronic Myeloid Leukemia A Disease of Young at Heart but Not of Body
Chronic Myeloid Leukemia A Disease of Young at Heart but Not of Body Jeffrey H Lipton, PhD MD FRCPC Staff Physician, Princess Margaret Cancer Centre Professor of Medicine University of Toronto POGO November,
More informationCME article CLINICAL TRIALS AND OBSERVATIONS
CLINICAL TRIALS AND OBSERVATIONS CME article Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party Gabriele Gugliotta, 1 Fausto
More informationDoes Generic Imatinib Change the Treatment Approach in CML?
Does Generic Imatinib Change the Treatment Approach in CML? Jerald P. Radich, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance NCCN.org For Clinicians NCCN.org/patients For Patients
More informationAllogeneic SCT for. 1st TKI. Vienna Austria. Dr. Eduardo Olavarría Complejo Hospitalario de Navarra
The International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) Berlin, Germany September 8-11, 2011 Vienna Austria Allogeneic SCT for CML Allogeneic after failure
More informationImpact of Age on Efficacy and Toxicity of Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis
Impact of Age on Efficacy and Toxicity of Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis Abstract 479 Giles FJ, Rea D, Baccarani M, Cross NCP, Steegmann
More informationStopping treatment how much we understand about mechanisms to stop successfully today, and where are the limits? Andreas Hochhaus
Stopping treatment how much we understand about mechanisms to stop successfully today, and where are the limits? Andreas Hochhaus Frankfurt I 27.5.2017 Aims of CML Therapy Leukemia cells >10 12 CHR 10
More informationMilestones and Monitoring
Curr Hematol Malig Rep (2015) 10:167 172 DOI 10.1007/s11899-015-0258-1 CHRONIC MYELOID LEUKEMIAS (E JABBOUR, SECTION EDITOR) Milestones and Monitoring Alessandro Morotti 1 & Carmen Fava 1 & Giuseppe Saglio
More informationt(9;22)(q34;q11) as part of a single or complex translocation, or BCR-ABL transcripts must be present in every case
CHRONIC MYELOID LEUKAEMIA Diagnostic Criteria Chronic phase CML t(9;22)(q34;q11) as part of a single or complex translocation, or BCR-ABL transcripts must be present in every case Maximally cellular marrow
More informationCurrent Monitoring for CML: Goals and. Jorge Cortes, MD Chief, CML & AML Section Department of Leukemia MD Anderson Cancer Center
Current Monitoring for CML: Goals and Principles Jorge Cortes, MD Chief, CML & AML Section Department of Leukemia MD Anderson Cancer Center Survival in Early Chronic Phase CML MDACC 2009 The Philadelphia
More informationUpdated review of nilotinib as frontline treatment for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
For reprint orders, please contact: reprints@futuremedicine.com Updated review of nilotinib as frontline treatment for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia Nilotinib,
More informationStopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute
Stopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute Natural History of CML Accumulation of immature myeloid cells New cytogenetic changes Chronic Phase Accelerated Phase
More informationMolecular monitoring of CML patients
EHA, Education Session, CML Stockholm, 14 June 2013 Molecular monitoring of CML patients Martin C. Müller Medical Faculty Mannheim Ruprecht-Karls-University Heidelberg Mannheim, Germany Disclosures Research
More informationPost ASH Actualités LMC
Post ASH 2014 - Actualités LMC Actualités de première ligne LMC PC ENESTnd (6 ans) Dasision (5 ans) EPIC Spirit France (5 ans) Spirit 2 UK (5 ans) ENESTnd: Mise à jour à 6 ans Design = 846 ults with wly
More informationFuture of CML: ABL001 and other treatments in the pipeline. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
Future of CML: ABL001 and other treatments in the pipeline. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy Primitive sleeping BCR-ABL-positive leukemic stem cells are less
More informationAdecade ago imatinib mesylate, the first tyrosine
CHRONIC MYELOID LEUKEMIA: AFTER A DECADE OF IMATIINIB Monitoring disease response to tyrosine kinase inhibitor therapy in CML Timothy P. Hughes 1 and Susan Branford 1 1 Centre for Cancer Biology, Departments
More informationAn update on imatinib mesylate therapy in chronic myeloid leukaemia patients in a teaching hospital in Malaysia
Singapore Med J 2012; 53(1) : 57 An update on imatinib mesylate therapy in chronic myeloid leukaemia patients in a teaching hospital in Malaysia Bee PC 1, MD, MMed, Gan GG 1, MBBS, FRCP, Tai YT 1, MBBS,
More informationExecutive summary Overview
Executive summary Overview In this appraisal, we have demonstrated that dasatinib is clinically more effective, as well as more cost effective, than imatinib, the current standard of care. In the pivotal
More informationCML UPDATE 2018 DAVID S. SNYDER, M.D. MARCH
CML UPDATE 2018 DAVID S. SNYDER, M.D. MARCH 15, 2018 Click to edit Master Presentation Date DISCLOSURES I have nothing to disclose 2001 2016 Loss in expectation of life of patients with chronic myeloid
More informationHSCT for Myeloproliferative Disorders. Jane Apperley
HSCT for Myeloproliferative Disorders Jane Apperley Myeloproliferative disorders CML Polycythemia vera Essential thrombocythemia Primary myelofibrosis bcr-abl + bcr-abl - JAK2 (valine to phenylalanin an
More informationChronic Myeloid Leukemia
Chronic Myeloid Leukemia Session Chair: Armand Keating, MD Speakers: Timothy Hughes, MD, MBBS; Michael J. Mauro, MD; and Jane F. Apperley, MBChB ABL Kinase Inhibitor Therapy for CML: Baseline Assessments
More informationAGGIORNAMENTI IN EMATOLOGIA Faenza, 7 Giugno 2018 LMC: ALGORITMI TERAPEUTICI ATTUALI E IL PROBLEMA DELLA RESISTENZA.
AGGIORNAMENTI IN EMATOLOGIA Faenza, 7 Giugno 2018 LMC: ALGORITMI TERAPEUTICI ATTUALI E IL PROBLEMA DELLA RESISTENZA Michele.Baccarani@unibo.it EUROPEAN LEUKEMIANET 2013 (Blood 2013;122:885 892). RESPONSE
More informationCancer Biology 2016;6(1) Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia patients in Upper Egypt. Mervat M.
Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia patients in Upper Egypt Mervat M. Omar Department of Oncology, Assuit University Hospital, Assuit, Egypt drmervatomar@yahoo.com Abstract: Background
More informationIl controllo della malattia minima residua Daniela Cilloni Università di Torino
Milano, 18-21 ottobre 2009 Il controllo della malattia minima residua Daniela Cilloni Università di Torino Response to imatinib Two main aspects to be considered: Degree of response Time to achieve it
More informationGreater Manchester and Cheshire Cancer Network Chronic Myeloid Leukaemia v3 2012
Greater Manchester and Cheshire Cancer Network Chronic Myeloid Leukaemia v3 2012 Dr Simon Watt Dr Shiva Natarajan 1.0 Introduction The landscape in chronic myeloid leukaemia (CML) has changed dramatically
More informationDeep molecular responses for treatment- free remission in chronic myeloid leukemia
Cancer Medicine REVIEW Open Access Deep molecular responses for treatment- free remission in chronic myeloid leukemia Stéphanie Dulucq 1 & Francois-Xavier Mahon 2 1 Laboratoire d Hématologie, Centre Hospitalier
More informationDAVID S. SNYDER, M.D.
CML UPDATE 2019 DAVID S. SNYDER, M.D. MARCH 21,2019 Click to edit Master Presentation Date Disclosures I do not have anything to disclose 2001 2016 Loss in expectation of life of patients with chronic
More informationPhiladelphia-positive Acute Lymphoblastic Leukemia
Philadelphia-positive Acute Lymphoblastic Leukemia Nicolas Boissel Service d Hématologie Unité Adolescents et Jeunes Adultes Hôpital Saint-Louis, Paris Ph+ acute lymphoblastic leukemia DR+, CD19+, CD22+,
More informationHorizon Scanning in Oncology
Horizon Scanning in Oncology Nilotinib (Tasigna ) for the 1 st -line treatment of Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase DSD: Horizon Scanning in Oncology Nr. 15
More information15 th Annual Miami Cancer Meeting
15 th Annual Miami Cancer Meeting CLL and CML Mohamed A. Kharfan-Dabaja, MD, MBA, FACP Director, Blood and Marrow Transplantation and Cellular Therapies Mayo Clinic Jacksonville, FL 15 th Annual Miami
More informationTalpaz M. et al. Dasatinib in Imatinib-resistant Philadelphia chromosomepositive leukemias. N Engl J Med (2006) 354;24:
References Sprycel Talpaz M. et al. Dasatinib in Imatinib-resistant Philadelphia chromosomepositive leukemias. N Engl J Med (2006) 354;24:2531-2541. National Comprehensive Cancer Network. Clinical Practice
More informationNew Anti Leukemic treatments deserve a Cardioncology approach. Guido Gini AOU «Ospedali Riuniti» Università Politecnica delle Marche Ancona
New Anti Leukemic treatments deserve a Cardioncology approach Guido Gini AOU «Ospedali Riuniti» Università Politecnica delle Marche Ancona CML Is Linked to a Single Cytogenetic Abnormality: The Philadelphia
More informationAbstracts and notes on CML presentations 1 ASH 2012 Atlanta
Abstracts and notes on CML presentations 1 ASH 2012 Atlanta Steve O Brien, Newcastle University 1 Highlights... 1 2 Plenary session [3]... 4 3 CML Therapy I [163-168]... 4 4 CML Therapy II [913-918]...
More informationBlast Phase Chronic Myelogenous Leukemia
Blast Phase Chronic Myelogenous Leukemia Benjamin Powers, MD; and Suman Kambhampati, MD The dramatic improvement in survival with tyrosine kinase inhibitors has not been demonstrated in the advanced blast
More informationIn this issue of the journal two articles deal with different
EDITORIALS & PERSPECTIVES Monitoring treatment of chronic myeloid leukemia Michele Baccarani, 1 Fabrizio Pane, 2 and Giuseppe Saglio 3 1 Department of Hematology-Oncology "L. and A. Seràgnoli" University
More informationManaging Relapse of CML Using Therapeutic Imatinib Plasma Level
H&0 CLINICAL CASE STUDIES Managing Relapse of CML Using Therapeutic Imatinib Plasma Level Adedayo A. Onitilo, MD, MSCR, FACP 1 Jessica M. Engel, MSN, FNP-BC 2 Department of Hematology/Oncology, 1 Marshfield
More information